Xedge IV Injection contains Pantoprazole 40mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal conditions. Pantoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system located in the gastric parietal cells, thereby suppressing gastric acid secretion. This intravenous formulation is primarily used in patients who are unable to take oral medication or require rapid acid suppression, such as those with gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, erosive esophagitis, and peptic ulcer disease. Xedge IV Injection is also utilized for the prevention and treatment of stress ulcers in critically ill patients. The drug demonstrates a rapid onset of action and provides effective acid control, which facilitates mucosal healing and symptom relief. Administration should be performed under medical supervision, with dosage and duration tailored according to the severity of the condition and patient response. Common adverse effects may include headache, diarrhea, nausea, and injection site reactions, though it is generally well tolerated. Caution is advised in patients with hepatic impairment, and potential drug interactions should be considered. Xedge IV Injection offers a reliable and efficient option for managing acid-related disorders in clinical settings requiring intravenous therapy.